Barclays Maintains Overweight on Indivior Pharmaceuticals, Lowers Price Target to $43

Benzinga Newsdesk www.benzinga.com Negative 87.8%

Neg 87.8% Neu 0% Pos 0%

Barclays analyst Glen Santangelo maintains Indivior Pharmaceuticals (NASDAQ:INDV) with a Overweight and lowers the price target from $46 to $43.